USPTO Examiner HADDAD MOUSSA MAHER - Art Unit 3796

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18816526MULTI-MODAL PRESSURE SENSORAugust 2024March 2025Allow721NoNo
18541217SYSTEM FOR CONCUSSION ASSESSMENTDecember 2023December 2024Abandon1210NoNo
18385294SYSTEM AND METHOD OF ASSESSING INTRA-ARTERIAL FLUID VOLUME USING INTELLIGENT PULSE AVERAGING WITH INTEGRATED EKG AND PPG SENSORSOctober 2023November 2024Allow1320NoNo
18300745MULTI-MODAL PRESSURE SENSORApril 2023July 2024Allow1640NoNo
17874764ELECTRIC PULSE MASSAGE APPARATUS AND SYSTEMJuly 2022April 2025Abandon3310NoNo
17856208CARDIOVASCULAR DETECTION SYSTEM AND METHODJuly 2022May 2025Abandon3510NoNo
17829449SYSTEMS AND METHODS UTILIZING PHASE-BASED BIOMARKER IN THE BRAINJune 2022March 2025Abandon3310NoNo
17514393WEARABLE DEVICE AND METHOD OF GENERATING SIGNAL FOR CONTROLLING OPERATION OF ELECTRONIC DEVICEOctober 2021June 2025Abandon4320NoNo
17601378DIAGNOSISOctober 2021May 2024Abandon3211NoNo
17300719Method And Assembly For Predicting The Occurrence Of Heart Disease Within An IndividualOctober 2021September 2024Abandon3620YesNo
17438597MEASUREMENT METHOD AND APPARATUS FOR PERIOD INFORMATION OF BIOLOGICAL SIGNAL, AND ELECTRONIC DEVICESeptember 2021April 2025Abandon4340NoNo
17405479USER AWARE MICROCURRENT THERAPY DEVICEAugust 2021June 2025Allow4631YesNo
17392033STROKE DETECTION AND MITIGATIONAugust 2021December 2024Abandon4001NoNo
17384912Smart Wearable DeviceJuly 2021January 2025Abandon4121NoNo
17417892SYSTEM AND METHOD FOR MEASURING AND MANAGING SLEEP EFFICACY IN A NON-INVASIVE MANNERJune 2021September 2024Abandon3901NoNo
17354811AUTOREGULATION MONITORING USING DEEP LEARNINGJune 2021April 2025Abandon4540YesNo
17353793SYSTEM, METHOD, AND HEAD MOUNTED DISPLAY FOR CONSUSSION ASSESSMENTJune 2021February 2024Abandon3210NoNo
17308676METHOD AND DEVICE TO DETERMINE SLEEP APNEA OF A USERMay 2021May 2024Abandon3620YesNo
17229759System and Method of Measuring Venous Oxygen Saturation Using Intelligent Pulse Averaging With Integrated EKG and PPG SensorsApril 2021November 2023Allow3120YesNo
17284035A PREDICTIVE DIAGNOSTIC SYSTEM FOR A DISTRIBUTED POPULATION OF AUTOMATED EXTERNAL DEFIBRILLATOR DEVICESApril 2021February 2025Allow4720YesYes
17222863WEARABLE FOOTWEAR SENSOR ARRAYS FOR DETECTION OF CARDIAC EVENTS, BODY MOTION, AND MUSCULAR ACTIONSApril 2021March 2024Abandon3510NoNo
17222591Biometric Mood Sensing Apparatus and Method of UseApril 2021May 2024Abandon3811NoNo
17217200IMPLANTABLE CAPSULE AND GASTROESOPHAGEAL REFLUX DISEASE DETERMINING SYSTEM THEREOFMarch 2021November 2024Abandon4330NoNo
17181199MOBILE APPLICATION TO PROMPT PHYSICAL ACTION TO MEASURE PHYSIOLOGIC RESPONSE IN IMPLANTABLE DEVICEFebruary 2021November 2024Abandon4520YesNo
17263709MOBILE DIAGNOSTIC SYSTEM FOR THE EARLY DETECTION OF VASCULAR DISEASESJanuary 2021November 2024Abandon4620NoNo
17154112METHOD AND APPARATUS FOR MEASURING ROBUST PULSE RATE AND RESPIRATORY RATE USING FACIAL IMAGESJanuary 2021April 2025Abandon5160YesNo
17147561Electronic SkinJanuary 2021March 2024Abandon3820NoNo
17140545TECHNOLOGIES FOR DETERMINING A CONDITION OF A PATIENT USING LC RESONATOR DATAJanuary 2021March 2024Abandon3821NoNo
17136150APPARATUS AND METHOD FOR ESTIMATING BIO-INFORMATIONDecember 2020July 2024Allow4341YesNo
17255916IMPLANTABLE NEURAL STIMULATION DEVICE WITH TWO HEADERSDecember 2020April 2025Abandon5250YesNo
17115864SYSTEM AND METHOD FOR DETECTING HOT FLASHES BASED ON HEART RATE PATTERNSDecember 2020September 2024Abandon4540NoNo
17053425SYSTEM FOR MONITORING AND PROVIDING ALERTS OF A FALL RISK BY PREDICTING RISK OF EXPERIENCING SYMPTOMS RELATED TO ABNORMAL BLOOD PRESSURE(S) AND/OR HEART RATENovember 2020November 2024Abandon4820YesNo
17072145SYSTEMS AND METHODS FOR THE DETERMINATION OF AROUSAL STATES, CALIBRATED COMMUNICATION SIGNALS AND MONITORING AROUSAL STATESOctober 2020March 2025Abandon5321YesNo
17033358SYSTEM AND METHOD TO PREDICT A STATE OF DROWSINESS IN A SUBJECTSeptember 2020July 2024Abandon4520NoNo
17029295HEART RHYTHM PROCESSING METHOD, ELECTRONIC DEVICE, AND COMPUTER PROGRAMSeptember 2020December 2024Abandon5150YesNo
17006971HEART RATE VARIABILITY NOTIFICATION DEVICEAugust 2020April 2024Abandon4431NoNo
16943046SYSTEM AND METHOD OF PHOTOPLETHYSMOGRAPHY BASED HEART-RATE ESTIMATION IN PRESENCE OF MOTION ARTIFACTSJuly 2020March 2024Abandon4440YesNo
16921757STABILIZING ACCESSORY FOR ADHESIVE MEDICAL DEVICESJuly 2020March 2025Abandon5741NoNo
16858252CATHETER INCLUDING ONE OR MORE SENSORSApril 2020November 2024Abandon5442YesNo
16579763SURGICAL SYSTEM AND METHOD OF DISPLAYING INFORMATION IN THE SAMESeptember 2019November 2024Abandon6050NoYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HADDAD, MOUSSA MAHER.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
1
(50.0%)
Not Allowed After Appeal Filing
1
(50.0%)
Filing Benefit Percentile
82.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner HADDAD, MOUSSA MAHER - Prosecution Strategy Guide

Executive Summary

Examiner HADDAD, MOUSSA MAHER works in Art Unit 3796 and has examined 39 patent applications in our dataset. With an allowance rate of 15.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.

Allowance Patterns

Examiner HADDAD, MOUSSA MAHER's allowance rate of 15.4% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HADDAD, MOUSSA MAHER receive 2.51 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HADDAD, MOUSSA MAHER is 43 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +18.3% benefit to allowance rate for applications examined by HADDAD, MOUSSA MAHER. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 7.7% of applications are subsequently allowed. This success rate is in the 1% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 14.3% of cases where such amendments are filed. This entry rate is in the 9% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 100% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 100% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 6% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 45% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 44% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.